Gemcitabine plus epi-doxorubicin as first-line chemotherapy for bladder cancer in advanced or metastatic stage: A phase II

Anticancer Research

Volumn 22, Issue 5, 2002, Pages 2981-2984

  Neri, B ^a   Doni, L ^b   Fulignati, C ^b   Gemelli, M T ^b   Turrini, M ^b   Di Cello, V ^b   Dominici, A ^b   Mottola, A ^b   Raugei, A ^b   Ponchietti, R ^b   Cini, G ^b  

^a Oncological Day Hospital   (Italy)

^b NONE

Author keywords

Bladder cancer; Chemotherapy; Epidoxorubicin; Gemcitabine; Tumor response

Indexed keywords

ANTIEMETIC AGENT; EPIRUBICIN; GEMCITABINE; RECOMBINANT GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR;

ADULT; ADVANCED CANCER; AGED; ALOPECIA; ANEMIA; ARTICLE; BLADDER CANCER; BLADDER METASTASIS; BONE MARROW; BONE METASTASIS; CANCER COMBINATION CHEMOTHERAPY; CARDIOTOXICITY; CLINICAL ARTICLE; CLINICAL TRIAL; DISEASE ACTIVITY; DOSE CALCULATION; DOSE TIME EFFECT RELATION; DRUG EFFICACY; FEBRILE NEUTROPENIA; FEMALE; HEART FUNCTION; HUMAN; KIDNEY FUNCTION; LIVER FUNCTION; LIVER METASTASIS; LUNG METASTASIS; LYMPH NODE METASTASIS; MALE; NAUSEA; NEUROTOXICITY; NEUTROPENIA; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; PROGNOSIS; STOMATITIS; THROMBOCYTOPENIA; VOMITING;

ADULT; AGED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; DEOXYCYTIDINE; EPIRUBICIN; FEMALE; HUMANS; MALE; MIDDLE AGED; NEOPLASM METASTASIS; URINARY BLADDER NEOPLASMS;

EID: 0036765989     PISSN: 02507005     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (14)

1. Jensen OM, Estéve J, Moller H and Renard H: Cancer in the European Community and its Member States. Eur J Cancer 26:11676-1256, 1990.
2. Quilty PM, Duncan W, Chisholm GD et al: Results of surgery, following radical radiotherapy for invasive bladder cancer. Br J Urol 58:396-405, 1986.
3. Yagoda A: Chemotherapy of metastatic bladder cancer. Cancer 45:1879-1888, 1980.
4. Sternberg C, Yagoda A, Scher HI et al: Methotrexate, vinblastine, doxorubicin and cisplatin for advanced transitional cell carcinoma of the urothelium efficacy and patterns of response and relapse. Cancer 64:2448-2453, 1989.
5. van Moorsel CJ, Peters GJ, Pinedo HM et al: Gemcitabine: future prospects of single- agent and combination studies. Oncologist 2(3): 127-134, 1997.
6. Ganzina F: Epidoxorubicin as a new analog of doxorubicin: a preliminary overview of preclinical and clinical data. Cancer treat Rev 10: 1-22, 1983.
7. Neri B, Bartalucci S, Cinelli P et al: Clinical aspects of doxorubicin and epidoxorubicin cardiotoxicity in cancerous patients. Curr Ther Res 43: 609-618, 1988.
8. Angelucci A, Alesse E, Trotta I et al: Schedule-dependent and additive effects of doxorubicin and gemcitabine on tumor cell apoptosis. Tumori 83(4): 129-30, 1997.
9. Karnofsky DA and Burchenal JH: The clinical evaluation of chemotherapeutic agents. In: Evaluation of Chemotherapeutic Agents. McLeod (Ed). New York, Columbia University Press. pp.191-205, 1949.
10. Miller AB, Hoogstraten B, Staquet M et al: Reporting results in cancer treatment. Cancer 47(1): 207-214, 1981.
11. Logothetis CJ, Dexeus FH, Finn L et al: A prospective randomized trial comparing M-VAC and CISCA chemotherapy for patients with metastatic urothelial tumors. J Clin Oncol 8: 1050-1056, 1990.
12. Ponzato P, Bertelli G, Bruan F et al: Intensified M-VE chemotherapy with GCSF support as outpatients treatment for advanced bladder cancer. Anticancer Res 17: 2325-2327, 1997.
13. Vogelzang NJ and Stadler M: Gemcitabine and other new chemotherapeutic agents for the treatment of metastatic bladder cancer. Urology 53: 243-250, 1999.
14. Moore MJ, Winquist EW, Murray N et al: Gemcitabine plus cisplatin, an active regimen in advanced urothelial cancer: a phase II trial of the National Cancer Institute of Canada Clinical trials Group. J Clin Oncol 17: 2876-2881, 1999.